XML 36 R19.htm IDEA: XBRL DOCUMENT
v3.22.2.2

MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2022
Novartis Institutes for BioMedical Research, Inc. |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |
Revenues Recognized under Agreement | Revenues recognized under the agreement were as follows (in thousands):
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2022 |  | 2021 |  | 2022 |  | 2021
Revenue related to Novartis agreement: |  |  |  |  |  |  |
Recognition of upfront license fee | $ | 7,582 |  |  | $ | 9,093 |  |  | $ | 23,222 |  |  | $ | 22,852 |
Research services | 2,028 |  |  | 2,421 |  |  | 6,211 |  |  | 6,104 |
Total | $ | 9,610 |  |  | $ | 11,514 |  |  | $ | 29,433 |  |  | $ | 28,956 |
Biogen MA, Inc. |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |
Revenues Recognized under Agreement | Revenues recognized under the agreement were as follows (in thousands):
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2022 |  | 2021 |  | 2022 |  | 2021
Revenue related to Biogen agreement: |  |  |  |  |  |  |
Recognition of license and stand-ready fee | $ | 7,306 |  |  | $ | 7,306 |  |  | $ | 21,918 |  |  | $ | 21,918 |
Research services | 2,107 |  |  | 3,661 |  |  | 8,740 |  |  | 10,266 |
Total | $ | 9,413 |  |  | $ | 10,967 |  |  | $ | 30,658 |  |  | $ | 32,184 |
Kite Pharma, Inc. |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |
Revenues Recognized under Agreement | Revenues recognized under the agreement were as follows (in thousands):
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2022 |  | 2021 |  | 2022 |  | 2021
Revenue related to Kite agreement: |  |  |  |  |  |  |
Recognition of license and stand-ready fee | $ | 6,296 |  |  | $ | 6,296 |  |  | $ | 18,682 |  |  | $ | 18,682 |
Research services | 619 |  |  | 113 |  |  | 875 |  |  | 339 |
Total | $ | 6,915 |  |  | $ | 6,409 |  |  | $ | 19,557 |  |  | $ | 19,021 |
Sanofi S.A. |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |
Revenues Recognized under Agreement | Revenues recognized under the 2014 Collaboration Agreement were as follows (in thousands):
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2022 |  | 2021 |  | 2022 |  | 2021
Revenue related to Sanofi agreement: |  |  |  |  |  |  |
Recognition of upfront fee | $ | — |  |  | $ | (1,125) |  |  | $ | 677 |  |  | $ | (692) |
Research services | — |  |  | 1,125 |  |  | 2,126 |  |  | 2,417 |
Milestone achievement | — |  |  | (759) |  |  | 457 |  |  | (467) |
Total | $ | — |  |  | $ | (759) |  |  | $ | 3,260 |  |  | $ | 1,258 |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434 + Details
Name: | us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_SanofiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |